New U.S. study finds mRNA-1273.815, a monovalent vaccine targeting the Omicron XBB.1.5 variant, generates higher neutralizing antibody titers compared to its bivalent counterpart. The study supports updating to an XBB.1.5-based monovalent vaccine for the 2023-24 campaign to combat emerging variants.
Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics
Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a
January 30, 2024